Potential of telomerase-specific oncolytic adenovirus as an immunogenic drug producing synergy with anti-PD-1 therapy

被引：0

作者：

Kanaya, Nobuhiko ^{[1
]}

Kuroda, Shinji ^{[1
]}

Morihiro, Toshiaki ^{[1
]}

Kubota, Tetsushi ^{[1
]}

Tazawa, Hiroshi ^{[1
]}

Kikuchi, Satoru ^{[1
]}

Nishizaki, Masahiko ^{[1
]}

Kagawa, Shunsuke ^{[1
]}

Urata, Yasuo ^{[2
]}

Fujiwara, Toshiyoshi ^{[1
]}

机构：

[1] Okayama Univ, Dept Grastroenterol Surg, Okayama, Japan

[2] Oncolys BioPharma Inc, Tokyo, Japan

来源：

CANCER SCIENCE | 2018年 / 109卷

关键词：

Oncolytic virus; Immunotherapy;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-3178

引用

收藏

页码：1059 / 1059

页数：1

相关论文

共 23 条

[21] Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide
Weir, Genevieve M.
Hrytsenko, Olga
Quinton, Tara
Berinstein, Neil L.
Stanford, Marianne M.
Mansour, Marc
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2016, 4
[22] Sequential therapy with supercharged NK cells with either chemotherapy drug cisplatin or anti-PD-1 antibody decreases the tumor size and significantly enhances the NK function in Hu-BLT mice
Kaur, Kawaljit
Chen, Po-Chun
Ko, Meng-Wei
Mei, Ao
Senjor, Emanuela
Malarkannan, Subramaniam
Kos, Janko
Jewett, Anahid
[J]. FRONTIERS IN IMMUNOLOGY, 2023, 14
[23] Novel combinatorial therapy of oncolytic adenovirus AdV5/3-D24-ICOSL-CD40L with anti PD-1 exhibits enhanced anti-cancer efficacy through promotion of intratumoral T-cell infiltration and modulation of tumour microenvironment in mesothelioma mouse model
Garofalo, Mariangela
Wieczorek, Magdalena
Anders, Ines
Staniszewska, Monika
Lazniewski, Michal
Prygiel, Marta
Zasada, Aleksandra Anna
Szczepinska, Teresa
Plewczynski, Dariusz
Salmaso, Stefano
Caliceti, Paolo
Cerullo, Vincenzo
Alemany, Ramon
Rinner, Beate
Pancer, Katarzyna
Kuryk, Lukasz
[J]. FRONTIERS IN ONCOLOGY, 2023, 13